Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Oct;116(4):2237–2244. doi: 10.1111/j.1476-5381.1995.tb15059.x

Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

S M Gardiner 1, J E March 1, P A Kemp 1, J J Mullins 1, T Bennett 1
PMCID: PMC1908969  PMID: 8564254

Abstract

1. Hypertensive transgenic (TGR(mRen-2)27) (abbreviated to TG) rats (n = 6) and their normotensive Sprague-Dawley (SD) control strain (n = 7) were chronically instrumented for the measurement of cardiac haemodynamics. The hypertension in TG rats (mean blood pressure 181 +/- 9 mmHg) was entirely attributable to a reduction in total peripheral conductance (TG rats = 169 +/- 7, SD rats = 292 +/- 15 microliters min-1 mmHg-1 100g-1) since cardiac index was not different in the two strains (TG rats = 30.5 +/- 1.2, SD rats = 29.5 +/- 1.6 ml min-1 100g-1). 2. In other animals instrumented for the assessment of regional haemodynamics, the extent of peripheral vasoconstriction was similar in renal, mesenteric and hindquarters vascular beds in the TG rats (reduction in vascular conductance relative to SD rats = 42%, 46% and 49%, respectively). 3. During an 8 h observation period with saline infusion, or following injection of losartan (10 mg kg-1) in SD rats there was no hypotension or regional vasodilation. With infusion of the endothelin antagonist, SB 209670 (10 micrograms kg-1 min-1), there was a slight hypotension, but no significant vasodilation; co-administration of losartan and SB 209670 caused a similar profile of effect, although the hypotension was increased. 4. With the same experimental protocol in TG rats, losartan caused a biphasic, progressive fall in mean arterial blood pressure accompanied by renal, mesenteric and hindquarters vasodilation. Although the response to SB 209670 was not biphasic, its hypotensive and vasodilator effects were not different from those of losartan after 8 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
2237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bader M., Zhao Y., Sander M., Lee M. A., Bachmann J., Böhm M., Djavidani B., Peters J., Mullins J. J., Ganten D. Role of tissue renin in the pathophysiology of hypertension in TGR(mREN2)27 rats. Hypertension. 1992 Jun;19(6 Pt 2):681–686. doi: 10.1161/01.hyp.19.6.681. [DOI] [PubMed] [Google Scholar]
  2. Batin P., Gardiner S. M., Compton A. M., Bennett T. Differential regional haemodynamic effects of the non-peptide angiotensin II antagonist, DuP 753, in water-replete and water-deprived Brattleboro rats. Life Sci. 1991;48(8):733–739. doi: 10.1016/0024-3205(91)90087-r. [DOI] [PubMed] [Google Scholar]
  3. Böhm M., Moll M., Schmid B., Paul M., Ganten D., Castellano M., Erdmann E. Beta-adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension. 1994 Dec;24(6):653–662. doi: 10.1161/01.hyp.24.6.653. [DOI] [PubMed] [Google Scholar]
  4. Davenport A. P., Ashby M. J., Easton P., Ella S., Bedford J., Dickerson C., Nunez D. J., Capper S. J., Brown M. J. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond) 1990 Mar;78(3):261–264. doi: 10.1042/cs0780261. [DOI] [PubMed] [Google Scholar]
  5. Douglas S. A., Edwards R. M., Elliott J. D., Ohlstein E. H. In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. Br J Pharmacol. 1995 Jan;114(2):405–413. doi: 10.1111/j.1476-5381.1995.tb13241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Douglas S. A., Gellai M., Ezekiel M., Feuerstein G. Z., Elliott J. D., Ohlstein E. H. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension. 1995 Apr;25(4 Pt 2):818–822. doi: 10.1161/01.hyp.25.4.818. [DOI] [PubMed] [Google Scholar]
  7. Douglas S. A., Gellai M., Ezekiel M., Ohlstein E. H. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens. 1994 May;12(5):561–567. [PubMed] [Google Scholar]
  8. Emori T., Hirata Y., Ohta K., Kanno K., Eguchi S., Imai T., Shichiri M., Marumo F. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension. 1991 Aug;18(2):165–170. doi: 10.1161/01.hyp.18.2.165. [DOI] [PubMed] [Google Scholar]
  9. Endo T., Uchida Y., Matsumoto H., Suzuki N., Nomura A., Hirata F., Hasegawa S. Regulation of endothelin-1 synthesis in cultured guinea pig airway epithelial cells by various cytokines. Biochem Biophys Res Commun. 1992 Aug 14;186(3):1594–1599. doi: 10.1016/s0006-291x(05)81590-6. [DOI] [PubMed] [Google Scholar]
  10. Fujita K., Matsumura Y., Kita S., Miyazaki Y., Hisaki K., Takaoka M., Morimoto S. Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol. 1995 Mar;114(5):925–930. doi: 10.1111/j.1476-5381.1995.tb13292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gardiner S. M., Compton A. M., Bennett T. Regional haemodynamic effects of endothelin-1 and endothelin-3 in conscious Long Evans and Brattleboro rats. Br J Pharmacol. 1990 Jan;99(1):107–112. doi: 10.1111/j.1476-5381.1990.tb14662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T., Hughes B., Foulkes R. Differential effects of (+/-)-dobutamine and human alpha-CGRP on cardiac and on regional haemodynamics in conscious Long Evans rats. Br J Pharmacol. 1991 Jun;103(2):1500–1508. doi: 10.1111/j.1476-5381.1991.tb09817.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T. Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol. 1990 Nov;101(3):632–639. doi: 10.1111/j.1476-5381.1990.tb14132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hirth-Dietrich C., Stasch J. P., Ganten D., Luft F. C. Renal effects of captopril and nitrendipine in transgenic rats with an extra renin gene. Hypertension. 1994 May;23(5):626–631. doi: 10.1161/01.hyp.23.5.626. [DOI] [PubMed] [Google Scholar]
  15. Imai T., Hirata Y., Emori T., Yanagisawa M., Masaki T., Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992 Jun;19(6 Pt 2):753–757. doi: 10.1161/01.hyp.19.6.753. [DOI] [PubMed] [Google Scholar]
  16. Kanse S. M., Takahashi K., Lam H. C., Rees A., Warren J. B., Porta M., Molinatti P., Ghatei M., Bloom S. R. Cytokine stimulated endothelin release from endothelial cells. Life Sci. 1991;48(14):1379–1384. doi: 10.1016/0024-3205(91)90434-d. [DOI] [PubMed] [Google Scholar]
  17. Kurihara H., Yoshizumi M., Sugiyama T., Takaku F., Yanagisawa M., Masaki T., Hamaoki M., Kato H., Yazaki Y. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun. 1989 Mar 31;159(3):1435–1440. doi: 10.1016/0006-291x(89)92270-5. [DOI] [PubMed] [Google Scholar]
  18. Larivière R., Thibault G., Schiffrin E. L. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993 Mar;21(3):294–300. doi: 10.1161/01.hyp.21.3.294. [DOI] [PubMed] [Google Scholar]
  19. Lemmer B., Mattes A., Böhm M., Ganten D. Circadian blood pressure variation in transgenic hypertensive rats. Hypertension. 1993 Jul;22(1):97–101. doi: 10.1161/01.hyp.22.1.97. [DOI] [PubMed] [Google Scholar]
  20. Moriguchi A., Brosnihan K. B., Kumagai H., Ganten D., Ferrario C. M. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol. 1994 Apr;266(4 Pt 2):R1273–R1279. doi: 10.1152/ajpregu.1994.266.4.R1273. [DOI] [PubMed] [Google Scholar]
  21. Mullins J. J., Peters J., Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990 Apr 5;344(6266):541–544. doi: 10.1038/344541a0. [DOI] [PubMed] [Google Scholar]
  22. Nishikibe M., Tsuchida S., Okada M., Fukuroda T., Shimamoto K., Yano M., Ishikawa K., Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52(8):717–724. doi: 10.1016/0024-3205(93)90233-s. [DOI] [PubMed] [Google Scholar]
  23. Ohlstein E. H., Douglas S. A., Ezekiel M., Gellai M. Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S321–S324. doi: 10.1097/00005344-199322008-00084. [DOI] [PubMed] [Google Scholar]
  24. Ohlstein E. H., Nambi P., Douglas S. A., Edwards R. M., Gellai M., Lago A., Leber J. D., Cousins R. D., Gao A., Frazee J. S. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052–8056. doi: 10.1073/pnas.91.17.8052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Okada M., Fukuroda T., Shimamoto K., Takahashi R., Ikemoto F., Yano M., Nishikibe M. Antihypertensive effects of BQ-123, a selective endothelin ETA receptor antagonist, in spontaneously hypertensive rats treated with DOCA-salt. Eur J Pharmacol. 1994 Jul 11;259(3):339–342. doi: 10.1016/0014-2999(94)90665-3. [DOI] [PubMed] [Google Scholar]
  26. Plumpton C., Champeney R., Ashby M. J., Kuc R. E., Davenport A. P. Characterization of endothelin isoforms in human heart: endothelin-2 demonstrated. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S26–S28. doi: 10.1097/00005344-199322008-00009. [DOI] [PubMed] [Google Scholar]
  27. Theodorsson-Norheim E. Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med. 1987;17(2):85–99. doi: 10.1016/0010-4825(87)90003-5. [DOI] [PubMed] [Google Scholar]
  28. Villarreal F. J., MacKenna D. A., Omens J. H., Dillmann W. H. Myocardial remodeling in hypertensive Ren-2 transgenic rats. Hypertension. 1995 Jan;25(1):98–104. doi: 10.1161/01.hyp.25.1.98. [DOI] [PubMed] [Google Scholar]
  29. Warner T. D., Allcock G. H., Vane J. R. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207–213. doi: 10.1111/j.1476-5381.1994.tb13053.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Widdop R. E., Gardiner S. M., Kemp P. A., Bennett T. Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats. Br J Pharmacol. 1993 Mar;108(3):684–688. doi: 10.1111/j.1476-5381.1993.tb12861.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yoshida K., Yasujima M., Kohzuki M., Kanazawa M., Yoshinaga K., Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension. 1992 Sep;20(3):292–297. doi: 10.1161/01.hyp.20.3.292. [DOI] [PubMed] [Google Scholar]
  32. Yoshida K., Yasujima M., Kohzuki M., Tsunoda K., Kudo K., Kanazawa M., Yabe T., Abe K., Yoshinaga K. Chronic synergistic effect of endothelin-1 and angiotensin II on blood pressure in conscious rats. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S514–S516. doi: 10.1097/00005344-199100177-00147. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES